The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review

Overview

Journal Eur Urol

Specialty Urology

Date 2017 Nov 11

PMID 29122377

Citations 71

Authors

Mohammad Abufaraj

Guido Dalbagni

Siamak Daneshmand

Simon Horenblas

Ashish M Kamat

Ryu Kanzaki

Alexandre R Zlotta

Shahrokh F Shariat

Affiliations

Soon will be listed here.

Abstract

Context: The role of surgery in metastatic bladder cancer (BCa) is unclear.

Objective: In this collaborative review article, we reviewed the contemporary literature on the surgical management of metastatic BCa and factors associated with outcomes to support the development of clinical guidelines as well as informed clinical decision-making.

Evidence Acquisition: A systematic search of English language literature using PubMed-Medline and Scopus from 1999 to 2016 was performed.

Evidence Synthesis: The beneficial role of consolidation surgery in metastatic BCa is still unproven. In patients with clinically evident lymph node metastasis, data suggest a survival advantage for patients undergoing postchemotherapy radical cystectomy with lymphadenectomy, especially in those with measurable response to chemotherapy (CHT). Intraoperatively identified enlarged pelvic lymph nodes should be removed. Anecdotal reports of resection of pulmonary metastasis as part of multimodal approach suggest possible improved survival in well-selected patients. Cytoreductive radical cystectomy as local treatment has also been explored in patients with metastatic disease, although its benefits remain to be assessed.

Conclusions: Consolidative extirpative surgery may be considered in patients with clinically evident pelvic or retroperitoneal lymph nodal metastases but only if they have had a response to CHT. Surgery for limited pulmonary metastases may also be considered in very selected cases. Best candidates are those with resectable disease who demonstrate measurable response to CHT with good performance status. In the absence of data from prospective randomized studies, each patient should be evaluated on an individual basis and decisions made together with the patient and multidisciplinary teams.

Patient Summary: Surgical resection of metastases is technically feasible and can be safely performed. It may help improve cancer control and eventually survival in very selected patients with limited metastatic burden. In a patient who is motivated to receive chemotherapy and to undergo extirpative surgical intervention, surgery should be discussed with the patient among other consolidation therapies in the setting of multidisciplinary teams.

Citing Articles

Analysis of postoperative complications in bladder cancer patients.

Shi T, Yu D, Xu Y, Huang X Open Med (Wars). 2024; 19(1):20241069.

PMID: 39588382 PMC: 11587919. DOI: 10.1515/med-2024-1069.

LINC00461 promotes bladder cancer cells EMT through miR-518b/HNRNPUL1 axis.

Zhou Y, Zhao K, Li J, Peng C, Jin J, Chen J Discov Oncol. 2024; 15(1):419.

PMID: 39254804 PMC: 11387575. DOI: 10.1007/s12672-024-01294-5.

Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives.

Shi X, Wang X, Yao W, Shi D, Shao X, Lu Z Signal Transduct Target Ther. 2024; 9(1):192.

PMID: 39090094 PMC: 11294630. DOI: 10.1038/s41392-024-01885-2.

Efficacy of cytoreductive surgery for metastatic upper tract urothelial carcinoma: a Surveillance, Epidemiology and End Results (SEER) study of 508 patients.

Hu H, Lai S, Ni R, Wang M, Lai C, Ji J Transl Androl Urol. 2024; 13(6):983-993.

PMID: 38983475 PMC: 11228681. DOI: 10.21037/tau-23-619.

Exploring the Targets and Molecular Mechanisms of Curcumin for the Treatment of Bladder Cancer Based on Network Pharmacology, Molecular Docking and Molecular Dynamics.

Li J, Feng S, Wang X, Zhang B, He Q Mol Biotechnol. 2024; .

PMID: 38822913 DOI: 10.1007/s12033-024-01190-x.

References

Dodd P, McCaffrey J, Herr H, Mazumdar M, Bacik J, Higgins G . Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol. 1999; 17(8):2546-52. DOI: 10.1200/JCO.1999.17.8.2546. View

Herr H, Donat S . Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy. J Urol. 2000; 165(1):62-4; discussion 64. DOI: 10.1097/00005392-200101000-00015. View

Herr H, Faulkner J, Grossman H, Natale R, White R, Sarosdy M . Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004; 22(14):2781-9. DOI: 10.1200/JCO.2004.11.024. View

Vieweg J, Gschwend J, Herr H, Fair W . Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol. 1999; 161(2):449-54. View

Vargas H, Akin O, Schoder H, Olgac S, Dalbagni G, Hricak H . Prospective evaluation of MRI, ¹¹C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. Eur J Radiol. 2012; 81(12):4131-7. DOI: 10.1016/j.ejrad.2012.06.010. View

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4:1. PMC: 4320440. DOI: 10.1186/2046-4053-4-1. View

Kulkarni G, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P . Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. J Clin Oncol. 2017; 35(20):2299-2305. DOI: 10.1200/JCO.2016.69.2327. View

Rink M, Lee D, Kent M, Xylinas E, Fritsche H, Babjuk M . Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. BJU Int. 2012; 111(3 Pt B):E30-6. DOI: 10.1111/j.1464-410X.2012.11433.x. View

Lu Y, Chen J, Liang J, Wang H, Lin C, Lin W . Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol. 2011; 81(9):2411-6. DOI: 10.1016/j.ejrad.2011.07.018. View

10.

Heidenreich A, Wilop S, Pinkawa M, Porres D, Pfister D . Surgical resection of urological tumor metastases following medical treatment. Dtsch Arztebl Int. 2012; 109(39):631-7. PMC: 3475292. DOI: 10.3238/arztebl.2012.0631. View

11.

Shariat S, Chade D, Karakiewicz P, Ashfaq R, Isbarn H, Fradet Y . Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2009; 183(1):68-75. DOI: 10.1016/j.juro.2009.08.115. View

12.

Ghadjar P, Burkhard F, Gautschi O, Thalmann G, Studer U . Induction chemotherapy for unresectable urothelial carcinoma of the bladder. BJU Int. 2010; 107(6):894-7. DOI: 10.1111/j.1464-410X.2010.09574.x. View

13.

Steven K, Poulsen A . Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only. J Urol. 2007; 178(4 Pt 1):1218-23. DOI: 10.1016/j.juro.2007.05.160. View

14.

Abe T, Kitamura H, Obara W, Matsumura N, Tsukamoto T, Fujioka T . Outcome of metastasectomy for urothelial carcinoma: a multi-institutional retrospective study in Japan. J Urol. 2013; 191(4):932-6. DOI: 10.1016/j.juro.2013.11.004. View

15.

Apolo A, Ostrovnaya I, Halabi S, Iasonos A, Philips G, Rosenberg J . Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst. 2013; 105(7):499-503. PMC: 3691944. DOI: 10.1093/jnci/djt015. View

16.

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

17.

Massard C, Gordon M, Sharma S, Rafii S, Wainberg Z, Luke J . Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016; 34(26):3119-25. PMC: 5569690. DOI: 10.1200/JCO.2016.67.9761. View

18.

Guzzo T, Rogers C, Deng C, Bivalacqua T, Palapattu G, Bastian P . Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastatic disease. BJU Int. 2008; 102(11):1539-43. DOI: 10.1111/j.1464-410X.2008.07877.x. View

19.

Bex A, Ljungberg B, van Poppel H, Powles T . The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016. Eur Urol. 2016; 70(6):901-905. DOI: 10.1016/j.eururo.2016.07.005. View

20.

Kim T, Ahn J, You D, Jeong I, Hong B, Hong J . Pulmonary Metastasectomy Could Prolong Overall Survival in Select Cases of Metastatic Urinary Tract Cancer. Clin Genitourin Cancer. 2015; 13(4):e297-e304. DOI: 10.1016/j.clgc.2015.04.013. View